CIL0522D2402: A Multicenter, Open-Label, Sequential-Cohort, Dose-Escalation, 14-Day Study to Explore the Tolerability and Pharmacokinetics of Iloperidone (Fanapt®) 12 to 24 mg/day Followed by 26 Weeks of Flexible Dosing (6 to 24 mg/day) in Adolescent Pati

Principal Investigator: Robert Findling

This study aims to obtain tolerability, Pharmacokinetic, safety, and efficacy data in adolescent patients (aged 12 to 17 years) requiring treatment with an antipsychotic agent. The study has 2 parts: Part A, screening period, dose-escalation period, fixed-dose period, and a steady-state

pharmacokinetic assessment and Part B, an optional extension phase for an additional 26 weeks. During both parts of the study, the participants will be asked to visit the site for physical and medical exams, blood draws, holter monitoring, ECGs, urine tests, as well as behavioral assessments.